Drug intelligence / Profile preview

yupingfeng guizhi

Development stage: Unknown
Lead developer: Yunnan Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Yupingfeng Guizhi is a Traditional Chinese Medicine (TCM) herbal formulation, typically administered as granules, developed by The First Affiliated Hospital of Yunnan University of Chinese Medicine. It is primarily investigated for the treatment of rheumatoid arthritis (RA), specifically for patients with the wind-cold-dampness Bi syndrome who have been exposed to hormones. The formulation is a combination of the classical Yupingfeng San (Jade Windscreen Powder) and Guizhi (Cinnamon Twig). It is thought to modulate the intestinal flora and adrenal cortex function, potentially mitigating the side effects of long-term hormone therapy and addressing the underlying immune dysregulation in RA.

Other names: Yupingfeng Guizhi GranulesYuping Fengguizhi Granules

Beyond the preview

Go deeper on yupingfeng guizhi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on yupingfeng guizhi.

Explore the full profile